About the Nanopatch™ Technology

The Nanopatch is a silicone patch with thousands of small projections designed to hit abundant immune cells in the skin.  Professor Mark Kendall and his team have tested the Nanopatch and confirmed in animals improved immune responses compared to standard needle and syringe injection.  In animals treated with influenza vaccines, the Nanopatch induced immune responses achieved equivalent protection with 1/150th of the delivered dose; which was 10 times better than any other delivery system tested.  Other significant Nanopatch results have been published with the delivery of vaccines for Human Papilloma Virus (HPV), Human Simplex Virus (HSV 2), Chikungunya and West Nile Virus.
A vaccine is coated onto the Nanopatch, which could eliminate the need for the vaccines to be refrigerated when they are stored and transported, overcoming a key global challenge for vaccines. In the developed world about 14% of a vaccine’s costs are attributed to maintaining the cold chain and in the developing world, the cold chain impact on vaccines is even greater.  In Africa about half of vaccines aren’t working properly because of a breakdown in the cold chainl.